Reliance Life Sciences Pvt. Ltd.

Reliance Life Science Pvt. Ltd.

Geeta Ravindran

Satish Mahadeorao Totey

Khan Firdos Alam

Shabari Pradeep Tipnis

Harinarayana Rao

Arundhati Mandal

Jayant Kulkarni

Ameet Patki

Pai Rajarshi

Rajarshi Pal

Bipasha Bose

Khanna Aparna

Alam Firdos Kahn

Subhadra Devi Kashyap

Tipnis Shabri

Aparna Khanna

The present disclosure describes the generation of neural cells and neurons from mammalian pluripotent embryonic-like stem cells (ELSCs) isolated from corneal limbal tissue, a non-embryonic tissue. Specifically, the present disclosure describes the generation of neuroprogenitor cells and differentiated dopaminergic neurons from ELSCs. The disclosed methods demonstrate the potential of ELSCs as a therapeutic tool, and may provide new therapeutic alternatives for various diseases, conditions, and injuries. Neuroprogenitor cells generated from ELSCs isolated from corneo-limbal tissue were transplanted into a rat model of Parkinson's disease, and were able to alleviate motor abnormalities in the rats for at least six months.

Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof

The present disclosure describes mammalian pluripotent embryonic-like stem cells (ELSCs) isolated from corneal limbal tissue, a non-embryonic tissue. The ELSCs of the present disclosure are capable of proliferating in an in vitro culture, maintain the potential to differentiate into cells of endoderm, mesoderm, and ectoderm lineage in culture, and are capable of forming embryoid-like bodies when placed in suspension culture. Thus, these cells possess multi-lineage differentiation potential and self-renewing capability. ELSCs may be a promising therapeutic tool, and may provide new therapeutic alternatives for various diseases, conditions, and injuries.

Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof

Purified preparations of human embryonic stem cells with certain population-specific characteristics are disclosed. This preparation is characterized by the positive expression of the following pluripotent cell surface markers: SSEA-1 (&#x2212;); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); alkaline phosphatase (+), as well as a set of ES cell markers including Oct-4, Nanog, Rex1, Sox2, Thy1, FGF4, ABCG2, Dppa5, UTF1, Cripto1, hTERT, Connexin-43 and Connexin-45. The cells of the preparation are negative for lineage specific markers like Keratin 8, Sox-1, NFH (ectoderm), MyoD, brachyury, cardiac-actin (mesoderm), HNF-3 beta, albumin, and PDX1 (endoderm). The cells of the preparation are human embryonic stem cells, have normal karyotypes, exhibit high telomerase activity and continue to proliferate in an undifferentiated state after continuous culture for over 40 passages. The embryonic stem cell line Relicell&#x2122; hES1 also retains the ability, throughout the culture, to differentiate into cell and tissue types derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). Methods for isolating a human embryonic stem cell line are also disclosed.

Establishment of a human embryonic stem cell line using mammalian cells

The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as dopaminergic neurons and serotonergic neurons from pluripotent stem cells, for example human embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of cells positive for tyrosine hydroxylase, a specific marker for dopaminergic neurons, have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurological disorders such as Parkinson's disease.

Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells

Growing community of inventors

Maharashtra, India

Geeta Ravindran